993 related articles for article (PubMed ID: 8902575)
1. T-cell recognition of self peptides as tumor rejection antigens.
Kawakami Y; Rosenberg SA
Immunol Res; 1996; 15(3):179-90. PubMed ID: 8902575
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma antigens recognized by T lymphocytes.
Kawakami Y; Robbins PF; Rosenberg SA
Keio J Med; 1996 Jun; 45(2):100-8. PubMed ID: 8683899
[TBL] [Abstract][Full Text] [Related]
3. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response.
Tsomides TJ; Reilly EB; Eisen HN
Int Immunol; 1997 Feb; 9(2):327-38. PubMed ID: 9040014
[TBL] [Abstract][Full Text] [Related]
4. Immune recognition of self in immunity against cancer.
Houghton AN; Guevara-Patiño JA
J Clin Invest; 2004 Aug; 114(4):468-71. PubMed ID: 15314682
[TBL] [Abstract][Full Text] [Related]
5. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
6. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
7. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
8. Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.
Labarriere N; Pandolfino MC; Raingeard D; Le Guiner S; Diez E; Le Dréan E; Dreno B; Jotereau F
Int J Cancer; 1998 Oct; 78(2):209-15. PubMed ID: 9754654
[TBL] [Abstract][Full Text] [Related]
9. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigens discovery: perspectives for cancer therapy.
Wang RF
Mol Med; 1997 Nov; 3(11):716-31. PubMed ID: 9407548
[TBL] [Abstract][Full Text] [Related]
11. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
Yu Z; Theoret MR; Touloukian CE; Surman DR; Garman SC; Feigenbaum L; Baxter TK; Baker BM; Restifo NP
J Clin Invest; 2004 Aug; 114(4):551-9. PubMed ID: 15314692
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
13. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.
Rubio-Godoy V; Dutoit V; Zhao Y; Simon R; Guillaume P; Houghten R; Romero P; Cerottini JC; Pinilla C; Valmori D
J Immunol; 2002 Nov; 169(10):5696-707. PubMed ID: 12421949
[TBL] [Abstract][Full Text] [Related]
14. New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system.
Kawakami Y
Cornea; 2000 May; 19(3 Suppl):S2-6. PubMed ID: 10832714
[TBL] [Abstract][Full Text] [Related]
15. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
16. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
17. Direct analysis of tumor-associated peptide antigens.
Slingluff CL; Hunt DF; Engelhard VH
Curr Opin Immunol; 1994 Oct; 6(5):733-40. PubMed ID: 7530012
[TBL] [Abstract][Full Text] [Related]
18. [Human tumor-rejection antigens and peptides from genes to clinical research].
Itoh K; Yamana H; Shichijo S; Yamada A
Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
[TBL] [Abstract][Full Text] [Related]
19. Role of the MHC restriction during maturation of antigen-specific human T cells in the thymus.
Hesnard L; Legoux F; Gautreau L; Moyon M; Baron O; Devilder MC; Bonneville M; Saulquin X
Eur J Immunol; 2016 Mar; 46(3):560-9. PubMed ID: 26635029
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
